Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=11484066&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Xemilofiban/orbofiban: insight into drug development Anders R; Kleiman J; Nicholson N; Wazowicz B; Burns DCardiovasc Drug Rev 2001[Sum]; 19 (2): 116-32A number of studies have reported on the successful use of intravenous glycoprotein IIb/IIIa receptor antagonists in patients with unstable angina or undergoing percutaneous interventions. The promise of interrupting the aggregation of platelets in the setting of unstable plaques on a chronic basis had led to the evaluation of several oral agents for longer-term administration. The development program of two of these agents, xemilofiban and orbofiban, will be reviewed and evaluated to understand the selection process of therapeutic targets for use based upon complex pharmacokinetic and pharmacodynamic responses. A review of the pivotal phase III trial results will also be provided along with insights into the potential reasons for the lack of significant benefit shown with these agents to date.|Alanine/*pharmacology[MESH]|Angina, Unstable/drug therapy[MESH]|Animals[MESH]|Benzamidines/*pharmacology[MESH]|Bleeding Time[MESH]|Clinical Trials, Phase II as Topic[MESH]|Clinical Trials, Phase III as Topic[MESH]|Coronary Thrombosis/prevention & control[MESH]|Drug Evaluation, Preclinical[MESH]|Humans[MESH]|Myocardial Infarction/prevention & control[MESH]|Platelet Aggregation Inhibitors/*pharmacology[MESH]|Platelet Aggregation/drug effects[MESH]|Platelet Glycoprotein GPIIb-IIIa Complex/metabolism[MESH]|Pyrrolidines/*pharmacology[MESH] |
